Leishmanicidal candidate LASSBio-1736, a cysteine protease inhibitor with favorable pharmacokinetics: low clearance and good distribution

References

• Alves MA, de Queiroz AC, Alexandre-Moreira MS, et al. (2015). Design, synthesis and in vitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives. Eur J Med Chem 100:24–33
   PubMed Web of Science ®Google Scholar
• Athanasiou LV, Saridomichelakis MN, Kontos VI, et al. (2013). Treatment of canine leishmaniosis with aminosidine at an optimized dosage regimen: a pilot open clinical trial. Vet Parasitol 192:91–7
   PubMed Web of Science ®Google Scholar
• Bauer M, Karch R, Zeitlinger M, et al. (2015). Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study. J Cereb Blood Flow Metab 35:743–6
   PubMed Web of Science ®Google Scholar
• Bergstrand M, Hooker AC, Wallin JE, et al. (2011). Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143–51
   PubMed Web of Science ®Google Scholar
• Bessegato TC, Niehues M, Buqui G, et al. (2016). Development and validation of a UHPLC-MS/MS bioanalytical method to quantify in plasma the analgesic candidate PT-31 following a preliminary pharmacokinetic study in rats. Biomed Chromatogr 30:852–6
   PubMed Web of Science ®Google Scholar
• Borborema SE, Osso JA, Jr Andrade HF, Jr, Nascimento N. (2013). Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice. Mem Inst Oswaldo Cruz 108:623–30
   PubMed Web of Science ®Google Scholar
• Brazil . (2008). Lei 11794/08. Procedimentos para Uso Científico de Animais. In: Diário oficial da união SddodC, ed. Brasilia, Brazil: Brazil
   Google Scholar
• Brazil . (2013). Diretriz Brasileira para o cuidado e a utilização de animais para fins científicos e didáticos. In: Ministério da Ciência TeICNdCdEAC, ed. Brasilia: MCTI, Brazil
   Google Scholar
• Caldwell GW, Masucci JA, Yan Z, Hageman W. (2004). Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur J Drug Metab Pharmacokinet 29:133–43
   PubMed Web of Science ®Google Scholar
• Carter KC, Baillie AJ, Alexander J, Dolan TF. (1988). The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent. J Pharm Pharmacol 40:370–3
   PubMed Web of Science ®Google Scholar
• CEVS , (2011). Available at: http://www.saude.rs.gov.br/upload/1337355106_v.13,%20n.1,%20mar.,%202011 [last accessed 22 Mar 2015]
   Google Scholar
• Conrado DJ, Verli H, Neves G, et al. (2008). Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. J Pharm Pharmacol 60:699–707
   PubMed Web of Science ®Google Scholar
• Conrado DJ, Fraga CA, Barreiro EJ, et al. (2007). High performance liquid chromatography method for quantification of the N-phenylpiperazine derivative LASSBio-579 in rat plasma. Quím Nova 30:1919–22
   Web of Science ®Google Scholar
• Cruz A, Rainey PM, Herwaldt BL, et al. (2007). Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis 195:602–8
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• Denis P, Ossenberg FW, Benhamou JP. (1975). Hepatic blood flow and enzyme induction in the rat. Biochem Pharmacol 24:249–51
   PubMed Web of Science ®Google Scholar
• Diehl KH, Hull R, Morton D, et al. (2001). A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21:15–23
   PubMed Web of Science ®Google Scholar
• Dorlo TP, Balasegaram M, Beijnen JH, de Vries PJ. (2012). Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 67:2576–97
   PubMed Web of Science ®Google Scholar
• Dorlo TP, Rijal S, Ostyn B, et al. (2014). Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. J Infect Dis 210:146–53
   PubMed Web of Science ®Google Scholar
• Du X, Guo C, Hansell E, et al. (2002). Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J Med Chem 45:2695–707
   PubMed Web of Science ®Google Scholar
• Fasinu P, Pillay V, Ndesendo VM, et al. (2011). Diverse approaches for the enhancement of oral drug bioavailability. Biopharm Drug Dispos 32:185–209
   PubMed Web of Science ®Google Scholar
• Han KH, Lee UY, Jang YS, et al. (2007). Differential regulation of B/K protein expression in proximal and distal tubules of rat kidneys with ischemia-reperfusion injury. Am J Physiol Renal Physiol 292:F100–6
   PubMed Web of Science ®Google Scholar
• Jha RK, Sah AK, Shah DK, Sah P. (2013). The treatment of visceral leishmaniasis: safety and efficacy. J Nepal Med Assoc 52:645–51
   PubMed Web of Science ®Google Scholar
• Kaiser M, Azeredo FJ, Beraldo HO, Costa TD. (2010). High performance liquid chromatography for determining a new anticonvulsant candidate, benzaldehyde semicarbazone in rat plasma. J Liq Chromatogr Relat Technol 33:526–35
   Web of Science ®Google Scholar
• Kuhn E, Lavielle L. (2005). Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 49:1020–38
   Web of Science ®Google Scholar
• Martins-Melo FR, Lima Mda S, Ramos AN Jr , et al. (2014). Mortality and case fatality due to visceral leishmaniasis in Brazil: a nationwide analysis of epidemiology, trends and spatial patterns. PLoS One 9:e93770
   PubMed Web of Science ®Google Scholar
• Moraes BK, Bajerski L, Parisotto A, et al. (2016). Simple HPLC-UV for the quantification of a new leishmanicidal candidate (E)-1-4(trifluoromethyl) benzylidene)-5-(2-4-dichlorozoyl) carbonylhydrazine (LASSBio-1736) in rat plasma for pharmacokinetics assessment. Biomed Chromatogr 30:1029–35
   PubMed Web of Science ®Google Scholar
• Moreira Lima L, Lacerda Barreiro EJd, Amaral Alves M. (2014). Hydrazide-n-acylhydrazone compounds, method for producing hydrazide-n-acylhydrazone compounds, use of intermediate compounds for producing hydrazide-n-acylhydrazones fof the treatment of leishmaniasis and chagas disease, and thus obtained pharmaceutical compositions. Rio de Janeiro, Brazil: Universidade Federal Do Rio De Janeiro UFDA
   Google Scholar
• Neervannan S. (2006). Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin Drug Metab Toxicol 2:715–31
   PubMed Web of Science ®Google Scholar
• Panchagnula R, Thomas NS. (2000). Biopharmaceutics and pharmacokinetics in drug research. Int J Pharm 201:131–50
   PubMed Web of Science ®Google Scholar
• Raghav NSM, Jangra S, Rohilla A, et al (2010). In vitro studies of various carbonyl derivatives on liver alkaline phosphatase. J Chem Pharma Res 4:801–7
   Google Scholar
• Rocco PRM, Xisto DG, Silva JD, et al. (2010). LASSBio-596: da descoberta aos ensaios pré-clínicos. Rev Virtual Quím 2:11–27
   Google Scholar
• Schettini DA, Costa Val AP, Souza LF, et al. (2005). Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate. Braz J Med Biol Res 38:1879–83
   PubMed Web of Science ®Google Scholar
• Schroder J, Noack S, Marhofer RJ, et al. (2013). Identification of semicarbazones, thiosemicarbazones and triazine nitriles as inhibitors of Leishmania mexicana cysteine protease CPB. PLoS One 8:e77460
   PubMed Web of Science ®Google Scholar
• Serrano DR, Hernandez L, Fleire L, et al. (2013). Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations. Int J Pharm 447:38–46
   PubMed Web of Science ®Google Scholar
• Shargel LWP, Yu ABC. (2005). Applied biopharmaceutics & pharmacokinetics. New York: McGraw-Hill, 267–9
   Google Scholar
• Steverding D, Sexton DW, Wang X, et al. (2012). Trypanosoma brucei: chemical evidence that cathepsin L is essential for survival and a relevant drug target. Int J Parasitol 42:481–8
   PubMed Web of Science ®Google Scholar
• Tasso L, Neves G, Menegatti R, et al. (2005). Pharmacokinetics and tissue distribution of a new heterocyclic N-phenylpiperazine derivative (LASSBio-581) in rats. Eur J Pharm Sci 26:194–202
   PubMed Web of Science ®Google Scholar
• Torres BG, Uchoa Fde T, Pigatto MC, et al. (2014). Pre-clinical pharmacokinetics and acute toxicological evaluation of a monastrol derivative anticancer candidate LaSOM 65 in rats. Xenobiotica 44:254–63
   PubMed Web of Science ®Google Scholar
• Voak AA, Harris A, Qaiser Z, et al. (2017). Treatment of experimental visceral leishmaniasis with single-dose liposomal amphotericin B–pharmacodynamics and biodistribution at different stages of disease. Antimicrob Agents Chemother 61:e00497–17
   PubMed Web of Science ®Google Scholar
• WHO [World Health Organization], (2015). Leishmaniases. Available at: http://www.who.int/leishmaniasis/research/en/ [last accessed 23 Mar 2017]
   Google Scholar